INNATE PHARMA (EPA:IPH) Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces its participation in Actionaria, a forum dedicated to meeting with individual investors, on November 18 & 19, in Paris

Transparency directive : regulatory news

04/11/2011 18:27

PRESS RELEASE

INNATE PHARMA ANNOUNCES ITS PARTICIPATION IN ACTIONARIA ON NOVEM BER 18 & 19 IN
PARIS

Marseilles, France, November 4, 2011

Innate Pharma SA (Euronext Paris: FR0010331421 - IPH), the innate immunity
company developing first-in-class drugs for cancer and inflammatory diseases,
announces its participation in Actionaria, a forum dedicated to meeting with
individual investors, on November 18 & 19, in Paris.

* Innate Pharma will present the Company and answer your questions at its
   stand (A16, level 1).

* Hervé Brailly, Chief Executive Officer, will be at the "Agora of
   Presidents" on Friday, November 18 at 11:25 am.

To receive electronic invitations to Actionaria, please visit our website
(www.innate-pharma.com). To receive paper invitations, please send an email to
investors@innate-pharma.com, stating your postal address and the desired number
of invitations.

Innate Pharma is committed to meet on a regular basis with the financial
community. Investors can also find updated information on the Company's website
and contact the investor relations team by writing to
investors@innate-pharma.com.

About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. Its innovative approach has been validated by licence agreements with two
major pharmaceutical companies, Novo Nordisk A/S and Bristol-Myers Squibb.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma
is based in Marseilles, France, and had 81 employees as at September 30, 2011.

Learn more about Innate Pharma at www.innate-pharma.com. Practical Information
about Innate Pharma shares:

ISIN code      FR0010331421
Ticker code    IPH

Disclaimer:
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Document de Reference prospectus
filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma's website.
This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:

Innate Pharma                  French enquiries
                               ATCG Press
Laure-Hélène Mercier           Marielle Bricman Director, Investor Relations
Phone: +33 (0)4 30 30 30 87    Mob.: +33 (0)6 26 94 18 53
investors@innate-pharma.com    mb@atcg-partners.com

International enquiries
M:Communications
Peter Laing, Amber Bielecka,
Hollie Vile
Phone: +44 (0)20 7920 2330
innatepharma@mcomgroup.com

111104 IPH - Actionaria

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces its participation in Actionaria, a forum dedicated to meeting with individual investors, on November 18 & 19, in Paris

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories